Mindset Pharma Inc. announced that the United States Patent and Trademark Office (USPTO) has granted allowance for another of Mindset's Family 1 patent applications, number 17/743,718, titled Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. Included in this patent are certain deuterated psilocybin analogs from Family 1. Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. This application is one of a family of applications having a priority date of February 4, 2020.
1st Jan change | Capi. | |
---|---|---|
+23.20% | 47.02B | |
+49.39% | 41.86B | |
-0.16% | 41.76B | |
-4.27% | 28.8B | |
+12.44% | 26.05B | |
-21.75% | 19.15B | |
+3.95% | 12.55B | |
+29.56% | 12.34B | |
-4.23% | 11.82B |